Brief: Cipher Pharmaceuticals Q2 Adjusted EBITDA USD 7.586 Million Vs. IBES Estimate USD 6.41 Million

Cipher Pharmaceuticals

07/08/2025 22:35

Corrects Key Details table to say revenue beat estimates, not missed

Overview

Cipher Q2 2025 revenue rises 152% yr/yr to quarterly record of $13.4 mln, beats estimates

Adjusted EBITDA for Q2 2025 grows 148% and beats analyst expectations

Company repaid $15 mln debt and repurchased $2.1 mln shares in Q2 2025

Outlook

Cipher aims to grow Natroba market share in U.S. anti-parasitic market

Company intends to acquire complementary dermatology products

Result Drivers

NATROBA SALES - Natroba sales in the U.S. contributed $7.8 mln, a sequential increase of 16% over Q1 2025

EPURIS GROWTH - Epuris sales volumes grew 14% in Q2 2025 compared to Q2 2024

LICENSING REVENUE DECLINE - Licensing revenue decreased due to competitive pressures and contractual royalty rate reductions

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$13.4 mln
$12.90 mln (4 Analysts)
Q2 Net Income
$5.89 mln
Q2 Adjusted EBITDA
Beat
$7.59 mln
$6.41 mln (4 Analysts)
Q2 EBITDA
$8.56 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Cipher Pharmaceuticals Inc is C$16.00, about 15.4% above its August 7 closing price of C$13.54

The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release: ID:nCNWytMNla

 (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)